Newly diagnosed and relapsed follicular lymphoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 25, Issue , 2014, Pages 76-82

  Dreyling, M ^a   Ghielmini, M ^b   Marcus, R ^c   Salles, G ^d   Vitolo, U ^e   Ladetto, M ^f  

^a UNIVERSITY OF MUNICH   (Germany)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e MOLINETTE HOSPITAL   (Italy)

^f C Arrigo Children's Hospital   (Italy)

^g ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IDELALISIB; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE SEVERITY; DISEASE SPECIFIC SURVIVAL; DRUG EFFICACY; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; MOLECULAR BIOLOGY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT DURATION; TREATMENT INDICATION; WATCHFUL WAITING; WESTERN EUROPE; HEALTH CARE PLANNING; LYMPHOMA, FOLLICULAR; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; STANDARDS; TUMOR RECURRENCE;

COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; LYMPHOMA, FOLLICULAR; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SOCIETIES, MEDICAL;

EID: 84911483017     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu200     Document Type: Article

References (42)

1. Tilly H, Vitolo U, Walewski J et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl. 7): vii78-vii82.
2. Ott G, Katzenberger T, Lohr A et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002; 99: 3806-3812.
3. Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-2169.
4. Montoto S, Corradini P, Dreyling M et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica 2013; 98: 1014-1021.
5. Sander B, de Jong D, Rosenwald A et al. The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. Haematologica 2014; 99: 715-725.
6. Cheson B, Fisher R, Barrington S et al. Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma-the Lugano Classification (in press).
7. Solal-Céligny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
8. Buske C, Hoster E, Dreyling M et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP) with respect to treatment outcome. Blood 2006; 108: 1504-1508.
9. Federico M, Bellei M, Marcheselli L et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27: 4555-4562.
10. Hoskin PJ, Kirkwood AA, Popova B et al. 4Gy versus 24Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol 2014; 15: 457-463.
11. Solal-Céligny P, Bellei M, Marcheselli L et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 2012; 30: 3848-3853.
12. Friedberg JW, Byrtek M, Link BK et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 2012; 30: 3368-3375.
13. Ardeshna KM, Smith P, Norton A et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advancedstage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516-522.
14. Ardeshna KM, Qian W, Smith P et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 2014; 15: 424-435.
15. Kahl BS, Hong F, Williams ME et al. Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood 2011; 118: LBA-6.
16. Feuerlein K, Zucca E, Ghielmini M. First-line treatment of follicular lymphoma: a patient-oriented algorithm. Leuk Lymphoma 2009; 50: 325-334.
17. Rummel M, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantlecell lymphoma: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210.
18. Flinn IW, van der Jagt R, Kahl BS et al. Randomized trial of bendamustinerituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123: 2944-2952.
19. Federico M, Luminari S, Dondi A et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013; 31: 1506-1513.
20. Marcus R, Imrie K, Solal-Céligny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisolone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579-4586.
21. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
22. Herold M, Haas A, Srock S et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986-1992.
23. Bachy E, Houot R, Morschhauser F et al. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica 2013; 98: 1107-1114.
24. Vitolo U, Ladetto M, Boccomini C et al. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. J Clin Oncol 2013; 31: 3351-3359.
25. Schulz H, Bohlius JF, Trelle S et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706-714.
26. Martinelli G, Schmitz SF, Utiger U et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28: 4480-4484.
27. Scholz CW, Pinto A, Linkesch W et al. (90)Yttrium-ibritumomab-tiuxetan as firstline treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 2013; 31: 308-313.
28. Huang YH, Hsiao LT, Hong YC et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772.
29. Seymour JF, Feugier P, Offner F et al. Updated 6year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Blood 2013; 122: abstr. 509.
30. Taverna CJ, Martinell M, Hitz F et al. Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: results of the randomized phase III trial SAKK 35/03. ASH 2013; 122; abstr. 508.
31. Morschhauser F, Radford J, Van Hoof A et al. 90yttrium-ibritumomab-tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow up of 7.3 years from the international, randomized, phase III first-line indolent trial. J Clin Oncol 2013; 31: 1977-1983.
32. Lopez-Guillermo A, Canales MA, Dlouhy I et al. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan (Zevalin) (Z) vs. maintenance with rituximab (R) for two years in patients with newly diagnosed follicular lymphoma (FL) responding to R-CHOP. Preliminary results at 36 months from randomization. ASH 2013; 122; abstr. 369.
33. Hiddemann W, Dreyling M, Metzner B et al. Evaluation of myeloablative therapy followed by autologous stem cell transplantation in first remission in patients with advanced stage follicular lymphoma after initial immuno-chemotherapy (R-CHOP) or chemotherapy alone: analysis of 940 patients treated in prospective randomized trials of the German Low Grade Lymphoma Study Group (GLSG). ASH 2013; 122; abstr. 419.
34. Vidal L, Gafter-Gvili A, Salles G et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011; 103: 1799-1806.
35. Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918-3927.
36. Sebban C, Brice P, Delarue R et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008; 26: 3614-3620.
37. Pettengell R, Schmitz N, Gisselbrecht C et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2013; 31: 1624-1630.
38. Trotman J, Fournier M, Lamy T et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 2011; 29: 3194-3200.
39. Luminari S, Biasoli I, Arcaini L et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 2013; 24: 2108-2112.
40. Louissaint A, Jr, Ackerman AM, Dias-Santagata D et al. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood 2012; 120: 2395-2404.
41. Gopal AK, Kahl BS, de Vos S et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008-1018.
42. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.